trending Market Intelligence /marketintelligence/en/news-insights/trending/tqeyjwmusr3y3dcvvxjilg2 content esgSubNav
In This List

Allergy Therapeutics allergy treatment clears midstage trial

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Allergy Therapeutics allergy treatment clears midstage trial

Allergy Therapeutics PLC said its allergy treatment cleared a midstage trial that was designed to determine the optimal dose that will be studied in a further study that begins in 2019.

The company is developing a treatment known as grass modified allergen tyrosine absorbed, or Grass MATA, for people allergic to grass pollen.

The treatment is designed to boosts the body's immune system to fight allergy.

The phase 2 trial, dubbed G205, studied different doses of the treatment to identify an optimal dose that can be researched further in a phase 3 trial.